| |
Steatotic liver disease and HIV: an agenda for 2030: 'PWH should be screened for fatty liver, steatosis'
|
| |
| |
Download the PDF here
"People living with HIV should be systematically screened for steatosis and advanced liver fibrosis in HIV clinics"
"in addition to its syndemic nature with other epidemics, the characteristics of HIV infection confer a special susceptibility to metabolically induced liver damage"
Conclusion
HIV and SLD are tightly interrelated epidemics whose relationships are mediated by macro-level, meso-level, and micro-level factors, such as shared social determinants, metabolic risk, stigma and low awareness among both the general population and health-care providers-all of which too often lead to late diagnoses and synergistic effects on liver damage. These issues render people living with HIV as a special population within the SLD spectrum. Therefore, the international scientific community should join forces to tackle this mounting public health threat, from public policies to tailored health system interventions, including screening and referral pathways, treatment adherence support, and clinical trials to pathophysiology studies.
Currently, steatotic liver disease (fatty liver disease, MASLD, MASH, NASH) is ignored by HIV clinicians, government officials & PWH, PWH do not get screened essentially except in special situations & PWH are not aware of this potential problem, which indeed is a comorbidity affecting aging & older PWH and is closely associated with heart disease, overweight, fat accumulation, diabetes & metabolic abnormalities, & HIV. Jules Levin, NATAP
| |
| |
| |
|
|
|
